Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR–p53–NF-κB interactions

References

• Pearl LH, Schierz AC, Ward SE, Al-Lazikani B, Pearl FM. Therapeutic opportunities within the DNA damage response. Nat Rev Cancer 2015; 15:166-80; PMID:25709118; http://dx.doi.org/10.1038/nrc3891
   PubMed Web of Science ®Google Scholar
• Aredia F, Scovassi AI. Poly(ADP-ribose): a signaling molecule in different paradigms of cell death. Biochem Pharmacol 2014; 92:157-63; PMID:24976506; http://dx.doi.org/10.1016/j.bcp.2014.06.021
   PubMed Web of Science ®Google Scholar
• Fatokun AA, Dawson VL, Dawson TM. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 2014; 171:2000-16; PMID:24684389; http://dx.doi.org/10.1111/bph.12416
   PubMed Web of Science ®Google Scholar
• Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011; 105:1114-22; PMID:21989215; http://dx.doi.org/10.1038/bjc.2011.382
   PubMed Web of Science ®Google Scholar
• Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, Hess AD, Smith BD, Karp JE, Kaufmann SH. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem 2014; 289:20543-58; PMID:24895135; http://dx.doi.org/10.1074/jbc.M114.549220
   PubMed Web of Science ®Google Scholar
• Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, Chen AP, Pommier Y, Doroshow JH, Yang SX. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle 2011; 10:4074-82; PMID:22101337; http://dx.doi.org/10.4161/cc.10.23.18170
   PubMed Web of Science ®Google Scholar
• Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005; 6:44-55; PMID:15688066; http://dx.doi.org/10.1038/nrm1546
   PubMed Web of Science ®Google Scholar
• Williamson CT, Kubota E, Hamill JD, Klimowicz A, Ye R, Muzik H, Dean M, Tu L, Gilley D, Magliocco AM, et al. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med 2012; 4:515-27; PMID:22416035; http://dx.doi.org/10.1002/emmm.201200229
   PubMed Web of Science ®Google Scholar
• Balmana J, Tung NM, Isakoff SJ, Grana B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol 2014; 25:1656-63; PMID:24827126; http://dx.doi.org/10.1093/annonc/mdu187
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12:852-61; PMID:21862407; http://dx.doi.org/10.1016/S1470-2045(11)70214-5
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33:244-50; PMID:25366685; http://dx.doi.org/10.1200/JCO.2014.56.2728
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382-92; PMID:22452356; http://dx.doi.org/10.1056/NEJMoa1105535
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15:852-61; PMID:24882434; http://dx.doi.org/10.1016/S1470-2045(14)70228-1
   PubMed Web of Science ®Google Scholar
• Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, Kim YH, Park JO, Chun HG, Zang DY, et al. Randomized, Double-Blind Phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol 2015; 33:3858-65; PMID:26282658; http://dx.doi.org/10.1200/JCO.2014.60.0320
   PubMed Web of Science ®Google Scholar
• Heitmann J, Geeleher P, Zuo Z, Weichselbaum RR, Vokes EE, Fetscher S, Seiwert TY. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. Oral Oncol 2014; 50:825-31; PMID:25017803; http://dx.doi.org/10.1016/j.oraloncology.2014.06.004
   PubMed Web of Science ®Google Scholar
• Nasuno T, Mimaki S, Okamoto M, Esumi H, Tsuchihara K. Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines. Cancer Sci 2014; 105:202-10; PMID:24219164; http://dx.doi.org/10.1111/cas.12322
   PubMed Web of Science ®Google Scholar
• Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013; 73:2271-80; PMID:23554447; http://dx.doi.org/10.1158/0008-5472.CAN-12-3000
   PubMed Web of Science ®Google Scholar
• Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res 2015; 75:628-34; PMID:25634215; http://dx.doi.org/10.1158/0008-5472.CAN-14-2593
   PubMed Web of Science ®Google Scholar
• Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 2013; 3:68-81; PMID:23103855; http://dx.doi.org/10.1158/2159-8290.CD-12-0049
   PubMed Web of Science ®Google Scholar
• Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008; 105:17079-84; PMID:18971340; http://dx.doi.org/10.1073/pnas.0806092105
   PubMed Web of Science ®Google Scholar
• Wagner LM. Profile of veliparib and its potential in the treatment of solid tumors. Onco Targets Ther 2015; 8:1931-9; PMID:26251615 http://dx.doi.org/10.2147/OTT.S69935
   PubMed Web of Science ®Google Scholar
• Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Lett 2002; 181:1-9; PMID:12430173; http://dx.doi.org/10.1016/S0304-3835(01)00795-9
   PubMed Web of Science ®Google Scholar
• Chow JP, Man WY, Mao M, Chen H, Cheung F, Nicholls J, Tsao SW, Li Lung M, Poon RY. PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. Mol Cancer Ther 2013; 12:2517-28; PMID:23979918; http://dx.doi.org/10.1158/1535-7163.MCT-13-0010
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, Popper H, Robin A, Commo F, Thomale J, et al. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Lung Cancer 2013; 80:216-22; PMID:23410825; http://dx.doi.org/10.1016/j.lungcan.2013.01.014
   PubMed Web of Science ®Google Scholar
• Ireno IC, Wiehe RS, Stahl AI, Hampp S, Aydin S, Troester MA, Selivanova G, Wiesmuller L. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53. Carcinogenesis 2014; 35:2273-82; PMID:25085902; http://dx.doi.org/10.1093/carcin/bgu160
   PubMed Web of Science ®Google Scholar
• Dey A, Tergaonkar V, Lane DP. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov 2008; 7:1031-40; PMID:19043452; http://dx.doi.org/10.1038/nrd2759
   PubMed Web of Science ®Google Scholar
• Zhuang C, Miao Z, Wu Y, Guo Z, Li J, Yao J, Xing C, Sheng C, Zhang W. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-kappaB pathway. J Med Chem 2014; 57:567-77; PMID:24428757; http://dx.doi.org/10.1021/jm401800k
   PubMed Web of Science ®Google Scholar
• Swindall AF, Stanley JA, Yang ES. PARP-1: Friend or Foe of DNA damage and repair in Tumorigenesis? Cancers (Basel) 2013; 5:943-58; PMID:24202328; http://dx.doi.org/10.3390/cancers5030943
   PubMedGoogle Scholar
• Weaver AN, Yang ES. Beyond DNA Repair: Additional functions of PARP-1 in cancer. Front Oncol 2013; 3:290; PMID:24350055; http://dx.doi.org/10.3389/fonc.2013.00290
   PubMedGoogle Scholar
• Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 2012; 72:5588-99; PMID:23118055; http://dx.doi.org/10.1158/0008-5472.CAN-12-2753
   PubMed Web of Science ®Google Scholar
• Nakamura M, Nakatani K, Uzawa K, Ono K, Uesugi H, Ogawara K, Shiiba M, Bukawa H, Yokoe H, Wada T, et al. Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R. Oncol Rep 2005; 14:1281-6; PMID:16211297
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-4; PMID:22588877; http://dx.doi.org/10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011; 17:7248-64; PMID:21868764; http://dx.doi.org/10.1158/1078-0432.CCR-11-0690
   PubMed Web of Science ®Google Scholar
• Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008; Chapter 10:Unit 10.1; PMID:18428421
   PubMedGoogle Scholar
• Faraoni I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S, Venditti A, et al. BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. Biochim Biophys Acta 2015; 1852:462-72; PMID:25483710; http://dx.doi.org/10.1016/j.bbadis.2014.12.001
   PubMed Web of Science ®Google Scholar